The most important, wide-reaching, and profound use case for AI might just be drug discovery. Normally it takes YEARS for scientists to develop drugs; AI can slash the timeline.

Kennedy Schaal is the CEO of Rejuve Bio, a startup that’s harnessing AI for faster drug discovery. And Jasmine Smith is the CEO of Rejuve AI, its sister company, which is racing to build a data-set that’s more equitable and inclusive and reflective of all humanity, with an end game of extending our longevity.

Kennedy and Jasmine discuss the current problems with drug discovery, how AI can help, and how AI can be especially impactful for more “niche diseases” that wouldn’t normally provide enough profit for Pharma companies to invest in.

Conversation with Rejuve Bio CEO Kennedy Schaal at (3:00).

Conversation with Rejuve AI CEO Jasmine Smith at (40:30).

Rejuve Biotech:
https://www.rejuve.bio

Rejuve AI:
https://www.rejuve.ai

Stay Connected:

• 🐦 Twitter/X
https://x.com/jeffwilser

• 💼 LinkedIn
https://www.linkedin.com/in/jeffwilser/

• 🖥️ JeffWilser.com
www.JeffWilser.com

🎧 Subscribe to AI-Curious:

• Apple Podcasts
https://podcasts.apple.com/us/podcast/ai-curious-with-jeff-wilser/id1703130308

• Spotify
https://open.spotify.com/show/70a9Xbhu5XQ47YOgVTE44Q?si=c31e2c02d8b64f1b

• YouTube Channel
https://www.youtube.com/@jeffwilser

AI for Drug Discovery and Longevity, w/ Rejuve CEOs Kennedy Schaal and Jasmine Smith